Wan Ben, Hu Hao, Wang Renxian, Liu Weifeng, Chen Dafu
Laboratory of Bone Tissue Engineering, Beijing Laboratory of Biomedical Materials, Beijing Research Institute of Traumatology and Orthopaedics, Beijing Jishuitan Hospital, Beijing, China.
Guangdong Provincial Key Laboratory of Orthopaedics and Traumatology, Guangzhou, China.
Front Oncol. 2020 Apr 15;10:370. doi: 10.3389/fonc.2020.00370. eCollection 2020.
Osteosarcoma is the most common malignant bone tumor in children and adolescents. Multiagent chemotherapy, together with surgical removal of all detectable lesions, has improved the long-term survival rate to 65-70% in patients with localized osteosarcoma and to 25-30% in patients with metastatic osteosarcoma since the 1970s. However, the conventional strategy has not improved in recent decades. With accumulating knowledge of the natural circular RNA (circRNA) pathogenesis of osteosarcoma, the diagnostic and therapeutic potential of some circRNAs has been explored. Meanwhile, artificial circular RNAs have been designed as onco-microRNA inhibitors to exert antitumor functions. Therefore, natural and artificial circular RNAs, like other RNA counterparts, are attractive new classes of therapeutic molecules for the treatment of osteosarcoma. This review summarizes the latest progress in the relationship between circRNAs and the malignant phenotype of osteosarcoma and sheds light on the therapeutic potential of the two types of circular RNA in the clinic.
骨肉瘤是儿童和青少年中最常见的恶性骨肿瘤。自20世纪70年代以来，多药化疗联合手术切除所有可检测到的病灶，已将局限性骨肉瘤患者的长期生存率提高到65%-70%，转移性骨肉瘤患者的长期生存率提高到25%-30%。然而，近几十年来，传统策略并未取得进展。随着对骨肉瘤天然环状RNA（circRNA）发病机制的认识不断积累，一些circRNA的诊断和治疗潜力已得到探索。同时，人工环状RNA已被设计为癌基因微小RNA抑制剂以发挥抗肿瘤功能。因此，天然和人工环状RNA与其他RNA类似物一样，是治疗骨肉瘤的有吸引力的新型治疗分子。本综述总结了circRNA与骨肉瘤恶性表型之间关系的最新进展，并阐明了这两种环状RNA在临床上的治疗潜力。
